Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Liz O'Riordan, FRCS, PhD

Advertisement
Liz O'Riordan, FRCS, PhD

Liz O'Riordan, FRCS, PhD

Articles by Liz O'Riordan, FRCS, PhD

O'Riordan

How Firsthand Breast Cancer Experience Shaped a Surgeon's Mission to Educate Colleagues and Empower Patients: With D. Ross Camidge, MD, PhD; and Liz O'Riordan, FRCS, PhD

ByRoss Camidge, MD, PhD,Liz O'Riordan, FRCS, PhD
June 18th 2025

D. Ross Camidge, MD, PhD sat down with Liz O'Riordan, FRCS, PhD, who describes herself as a breast surgeon who has had breast cancer.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on OncLive

    1

    European Approval Is Sought for Lirafugratinib in FGFR2-Altered Metastatic Cholangiocarcinoma

    2

    FDA Approves Taletrectinib for Locally Advanced or Metastatic ROS1+ NSCLC

    3

    TUB-040 Elicits Clinically Meaningful Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer

    4

    Dr Bianchi on the Mechanism of Anselamimab in AL Amyloidosis

    5

    PET-Guided Nivolumab Yields High Responses in Hodgkin Lymphoma

    • Advertise
    • About OncLive
    • Editorial Board
    • MJH Life Sciences brands
    • Contact Us
    • Privacy
    • Terms & Conditions
    • Do Not Sell My Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo
    Download on Apple
    Download on Google Play

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us